Unless you personally know a residency director, it’s difficult to connect with one. That’s where pharmacy conferences come in.
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today reported results for the third quarter ended Sept. 30, 2014. Net sales for the quarter were $1.2 billion and adjusted* diluted earnings per share were $0.74. (Adjusted* measures exclude specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles basis, third-quarter 2014 diluted earnings per share were $0.92.
Fifteen hospitals that use insulin pens will participate in ASHP’s Mentored Quality Improvement Impact Program for Insulin Pen Safety.
ASHP is pleased to announce the selection of PharmAcademic from the McCreadie Group, Inc., to support the evaluation of residents and to provide documentation of a systems-based approach to training for ASHP-accredited residencies under the new, recently-approved PGY1 residency standard.